Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 151-156

  Papatheodoridis, George V ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Adefovir; Entecavir; Hepatitis B; Interferon; Lamivudine; Telbivudine; Tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA; TELBIVUDINE; TENOFOVIR DISOPROXIL;

CREATINE KINASE BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG TOLERANCE; HEPATITIS B; HUMAN; HYPOPHOSPHATEMIA; MONOTHERAPY; MYOPATHY; NEPHROTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; REMISSION; REVIEW; SIDE EFFECT; TERATOGENICITY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; NUCLEOTIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872018689     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12054     Document Type: Review

References (44)

1. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008; 8: 167-78.
2. Lok ASF, Mcmahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
5. Hadziyannis SJ, Papatheodoridis GV. Hepatitis Be antigen negative chronic hepatitis B - natural history and treatment. Semin Liver Dis 2006; 26: 130-41.
6. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 2008; 15: 434-41.
7. Papatheodoridis GV, Manolakopoulos S, Liaw Y-F, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2012; 57: 196-202.
8. Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful serum HBV DNA cut-off level for therapeutic decisions in HBeAg-negative chronic hepatitis B virus infection? Hepatology 2008; 48: 1451-9.
9. Papatheodoridis GV. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. Liver Int 2011; 31(Suppl. 1): 95-103.
10. Vinayek R, Shakil O. Adverse events associated with interferon-alfa therapy in patients with chronic viral hepatitis. Viral Hep Rev 1997; 3: 167-77.
11. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
12. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185-95.
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
14. Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-34.
15. Manolakopoulos S, Striki A, Deutsch M, et al. Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver Int 2011; 31: 1525-32.
16. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
17. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
18. Marcellin P, Buti M, Gane EJ, et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011; 54(Suppl): 1011A.
19. Gane EJ, Deary G, Piratvisuth T, et al. Renal function is improved for chronic hepatitis B (CHB) patients treated with telbivudine. Hepatology 2011; 54(Suppl): 1044A.
20. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-96.
21. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-26.
22. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
23. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
24. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
25. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004; 64: 1-15.
26. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-9.
27. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-91.
28. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162-70.
29. Tenney D, Pokorowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2: S77.
30. Marcellin P, Heathcote EJ, Corsa A, et al. No detectable resistance to tenofovir disoproxil fumarate (TDF) following up to 240 weeks of treatment in patients with HBeAg+ and HBeAg- chronic hepatitis B virus infection. Hepatology 2011; 54(Suppl): 480A.
31. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011; 54: 443-51.
32. Van Bommel F, De Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
33. Berg T, Moller B, Trinh H, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV). J Hepatol 2008; 48(Suppl. 2): S34.
34. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 2010; 52: 493-500.
35. Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiol 2008; 3: 525-38.
36. Hadziyannis SJ, Sevastianos V, Rapti IN, Tassopoulos N. Sustained biochemical and virological remission after discontiuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology 2006; 44(Suppl. 1): 231A.
37. Lampertico P, Invernizzi F, Soffredini R, et al. Add-on Peg-IFN improves HBsAg kinetics in patients long-term fully suppressed by nucleos(t)ide analogues. J Hepatol 2012; 56(Suppl. 2): S207.
38. Chan HL, Wong GL, Chim AM, et al. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 2011; 16: 1249-57.
39. Bzowej NH. Hepatitis B therapy in pregnancy. Curr Hepat Rep 2010; 9: 197-204.
40. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-13.
41. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-79.
42. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-11.
43. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-56.
44. Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60: 1109-16.